MedTrace Logo

Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?

NCT02461901 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 203

Last updated 2021-09-09

No results posted yet for this study

Summary

This study evaluates whether patients with Clostridium difficile infection (CDI) who are treated with fidaxomicin have less contamination of their skin and surrounding environment with spores of C. difficile than patients treated with other drugs (metronidazole or vancomycin)

Conditions

  • Clostridium Difficile Infection

Interventions

OTHER

Environmental sampling

Sampling of five sites in the patient's immediate environment for C. difficile spores

OTHER

Skin swab sampling

Collection of swabs from three sites on the skin for C. difficile spores

OTHER

Fecal sampling

Collection of fecal samples for C. difficile spores

Sponsors & Collaborators

  • Astellas Pharma Europe Ltd.

    collaborator INDUSTRY

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • St George's Healthcare NHS Trust

    collaborator OTHER

  • Professor Mark Wilcox

    lead OTHER

Principal Investigators

  • Mark H Wilcox · Leeds Teaching Hospitals NHS Trust

  • Tim Planche · St George's Healthcare NHS Trust

  • Philip Stanley · Bradford Teaching Hospitals NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02461901 on ClinicalTrials.gov